Physician profile
Wendy R Frost
NPI 1215053186
$6,255.45
in general payments reported to CMS, 2019-2025
32 companies · $1,359 in 2025
The $1,359 reported for 2025 was more than what 98% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $793 · 2022: $1,734 · 2023: $1,419 · 2024: $951 · 2025: $1,359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,625 · Education: $103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,625.30 |
| Education | $103.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,028.25 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $840.05 | 2022-2025 | |
| Evofem Biosciences, INC. | $796.17 | 2021-2025 | Phexxi, Solosec, Phexx |
| Myovant Sciences INC. | $516.36 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $514.02 | 2023-2025 | Myfembree |
| Exeltis, USA INC. | $368.61 | 2021-2025 | Slynd |
| Astellas Pharma US INC | $349.34 | 2022-2025 | Veozah, Myrbetriq |
| Millicent US INC | $257.79 | 2024-2025 | Femlyv, Intrarosa |
| Agile Therapeutics, INC. | $172.79 | 2021-2024 | Twirla |
| Coopersurgical, INC. | $146.70 | 2022-2025 | Paragard T 380a, Paragard T 380a |
| Organon LLC | $143.60 | 2021-2024 | Nexplanon |
| Daiichi Sankyo INC. | $141.51 | 2022-2023 | Injectafer |
| Corium, LLC | $125.04 | 2023-2025 | Azstarys |
| Scynexis, INC. | $105.49 | 2022 | |
| Therapeuticsmd, INC. | $85.63 | 2021-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $85.39 | 2021-2022 | |
| Virtus Pharmaceuticals LLC | $79.55 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.97 | 2023-2025 | |
| Travere Therapeutics, INC. | $50.27 | 2025 | |
| Ascend Therapeutics US, LLC | $45.85 | 2022 | |
| Ironshore Pharmaceuticals INC. | $44.91 | 2024 | |
| Shield Therapeutics INC | $43.07 | 2024-2025 | |
| Ucb, INC. | $37.44 | 2025 | Rystiggo, Briviact |
| Pfizer INC. | $34.68 | 2022-2023 | |
| Neurelis, INC. | $31.31 | 2025 | Valtoco |
| Harmony Biosciences LLC | $25.95 | 2024 | |
| Hologic Sales and Service, LLC | $24.97 | 2025 | Thinprep 2000 Processor |
| Azurity Pharmaceuticals, INC. | $21.72 | 2023 | Adthyza |
| Vertical Pharmaceuticals, LLC | $19.78 | 2024 | Relexxii |
| Neos Therapeutics, Lp | $18.01 | 2023 | Adzenys Xr-Odt |
| Tris Pharma INC | $17.99 | 2025 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $16.24 | 2023 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wendy Frost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.